Emirates Scholar Research Center - Research Publishing & Indexing Center

Nanoparticles Ellagic Acid Protects Against Cisplatin-Induced Hepatotoxicity In Rats Without Inhibiting Its Cytotoxic Activity

Conference: 4th International Conference In Prophetic Medicine Research

Keywords: Nanoparticles ellagic acid, cisplatin, hepatotoxicity


Background and Objective

Ellagic acid (ELL) is a phenolic constituent of natural sources with antioxidant and anti-inflammatory activities. The ELL has a low bioavailability,therefore a nanoparticles (NP ELL) was formulated to

determine whether NP ELLcould alleviate cisplatin (CISP)-induced hepatotoxicity in comparison to a high dose of regular ELL.

Materials and Methods

The NP ELL was prepared using an emulsion solvent diffusion technique. Hepatotoxicity was induced in rats using CISP (7.5 mg kgG). 1Rats were pre-treated with either 10 ELL (10 mg kgG) 1 NP ELL (1 mg kgG) or 2 NP ELL (2 mg kgG)


All ELL regimens significantly decreased CISP-induced increases in liver enzymes, MDA, NO, TNF-”, NFkB and BAX. Additionally, all significantly restored hepatic GSH, GPx, CAT and Bcl-2. Ratʼs liver showed no injury in all ELL pretreated groups. Importantly, NP ELL did not inhibit the cytotoxic effect CISP against HCT116 cell lines.


The NP ELL has improved bio-availability and protected against CISP induced hepatotoxicity. This provides an encouraging way of ameliorating the bio-availability of ELL while sustaining its desirable therapeutic effects.

Scroll to top
Browse Tags